Patents by Inventor Majid Mehtali
Majid Mehtali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110251085Abstract: The present invention relates to the field of virology. More precisely, the invention provides a method of determining the ability of a test compound to modulate the biological activity of a variant of a target protein, wherein said test compound is previously known to modulate the biological activity of said protein. This invention is useful to determine whether a drug candidate, such as anti-viral compounds (eg. against hepatitis C virus: NS5B, NS3), active against a target protein is active against a variant of said protein (eg. polymorphisms, genotypes or mutants).Type: ApplicationFiled: March 16, 2009Publication date: October 13, 2011Applicant: VIVALISInventors: Mehdi Lahmar, Isabelle Valarche, Majid Mehtali
-
Publication number: 20100235937Abstract: Method of culturing embryonic stem (ES) cells of avian origin includes the steps of: a) suspending ES cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF); and animal serum; and, optionally, at least one growth factor selected from among interleukin 6 (II-6), interleukin 6 receptor (II-6R), stem cell factor (SCF), fibroblast growth factor (FGF), leukemia inhibitory factor (LIF), interleukin 11 (II-11), oncostatin and/or cardiotrophin; b) seeding the suspension of ES cells obtained in step a) on a layer of feeder cells and further culturing the ES cells for at least 2 to 10 passages; c) optionally, removing at least one growth factor selected from among SCF, FGF, II-6, II-6R, LIF, oncostatin, cardiotrophin and II-11 from the culture medium; and d) further culturing the ES cells in the medium of step c) on a layer of feeder cells.Type: ApplicationFiled: August 9, 2007Publication date: September 16, 2010Inventors: Isabelle Valarche, Luc Batard, Majid Mehtali
-
Publication number: 20100226912Abstract: The invention generally relates to the field of recombinant protein production. More particularly, the invention relates to the use of avian embryonic derived stem cell lines, named EBx®, for the production of proteins and more specifically glycoproteins such as antibodies. The invention is useful for the production of monoclonal IgG1 antibody subtype having high cell-mediated cytotoxic activity. The invention relates to the use of such antibodies as a drug to treat cancers and inflammatory diseases.Type: ApplicationFiled: May 21, 2008Publication date: September 9, 2010Applicant: VIVALISInventor: Majid Mehtali
-
Publication number: 20100062489Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from duck embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: ApplicationFiled: April 23, 2008Publication date: March 11, 2010Applicant: VIVALISInventors: Fabienne Guehenneux, Karine Moreau, Magali Esnault, Majid Mehtali
-
Publication number: 20090081251Abstract: The present invention relates to the development and manufacturing of viral vaccines, particularly the industrial production of viral vectors and vaccines, and more particularly the use of avian embryonic stem cells, preferably the EBx cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses; the invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: ApplicationFiled: April 11, 2006Publication date: March 26, 2009Applicant: VIVALISInventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
-
Patent number: 7482155Abstract: The present invention concerns a chimeric construct comprising a SMC-specific promoter operably linked to a muscle-specific enhancer. It also provides an expression cassette comprising such a chimeric construct to control expression of a therapeutic gene. Finally, the invention relates to a recombinant vector, a viral particle, an eukaryotic host cell, a composition comprising said expression cassette and their use for specific expression in SMCs and for therapeutic or prophylactic purposes, a method for the treatment of a human or animal organism as well as a transgenic non-human animal comprising integrated into its genome the chimeric construct, the expression cassette or the vector of the present invention.Type: GrantFiled: July 4, 2001Date of Patent: January 27, 2009Assignee: Transgene S.A.Inventors: Sébastien Ribault, Pascal Neuville, Majid Mehtali
-
Publication number: 20080199433Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: ApplicationFiled: April 11, 2007Publication date: August 21, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, Majid Mehtali
-
Publication number: 20080076669Abstract: The present invention relates to a screening technology that allows the isolation of peptides able to bind to target protein, the binding of which being sensitive to the protein conformation. The invention further provides a method to identify compounds that specifically and precisely modify the protein conformation and its biological activity. Finally, the invention relates to certain peptides obtained by the method of screening of the present invention and their use as therapeutic agent for the prevention or treatment of diseases.Type: ApplicationFiled: September 16, 2005Publication date: March 27, 2008Inventor: Majid Mehtali
-
Patent number: 7344883Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: GrantFiled: June 24, 2005Date of Patent: March 18, 2008Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, Majid Mehtali
-
Patent number: 7256036Abstract: The invention relates to an adenovirus fiber modified by the mutation of one or more residues. The residues are directed towards the natural cell receptor in the three-dimensional structure of said adenovirus. The invention further relates to a DNA fragment, and expression vector, and a cell line expressing said fiber, and also concerns an adenovirus, the process for producing this type of adenovirus, and an infectable host cell, as well as their therapeutic application and a corresponding pharmaceutical composition.Type: GrantFiled: April 1, 2003Date of Patent: August 14, 2007Assignee: TransgeneInventors: Valérie Legrand, Majid Mehtali, Pierre Boulanger
-
Patent number: 7250293Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35-E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.Type: GrantFiled: October 15, 2002Date of Patent: July 31, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
-
Publication number: 20060140920Abstract: Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector for the expression of one or more proteins capable of forming a multimer, viral particles and cells containing the adenoviral vector, a pharmaceutical composition and its therapeutic use.Type: ApplicationFiled: October 6, 2005Publication date: June 29, 2006Applicant: TRANSGENE S.A.Inventors: Pierre Leroy, Majid Mehtali
-
Patent number: 7067309Abstract: Novel defective adenoviruses for the transfer and expression of an exogenous nucleotide sequence in a host cell or organism. The invention also relates to novel complementation lines and to the process for the preparation of these novel defective adenoviruses and their use in therapy and to a pharmaceutical composition containing same.Type: GrantFiled: December 19, 2000Date of Patent: June 27, 2006Assignee: Transgene S.A.Inventors: Jean-Luc Imler, Majid Mehtali, Andréa Pavirani
-
Patent number: 7005277Abstract: Novel defective adenoviruses for the transfer and expression of an exogenous nucleotide sequence in a host cell or organism. The invention also relates to novel complementation lines and to the process for the preparation of these novel defective adenoviruses and their use in therapy and to a pharmaceutical composition containing same.Type: GrantFiled: November 30, 2000Date of Patent: February 28, 2006Assignee: Transgene S.A.Inventors: Jean-Luc Imler, Majid Mehtali, Andréa Pavirani
-
Publication number: 20050277194Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: ApplicationFiled: June 24, 2005Publication date: December 15, 2005Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
-
Patent number: 6974695Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination.Type: GrantFiled: November 15, 2001Date of Patent: December 13, 2005Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo J. E. Havenga, Majid Mehtali
-
Patent number: 6960469Abstract: Genetically modified cell implant comprising an exogenous nucleotide sequence coding for all or part of an antibody, method for the preparation of such an implant and its therapeutic use for the treatment or prevention of an acquired disease. The invention also concerns an adenoviral vector, a pharmaceutical composition and its therapeutic use.Type: GrantFiled: August 13, 2001Date of Patent: November 1, 2005Assignee: Transgene S.A.Inventors: Pierre Leroy, Majid Mehtali
-
Patent number: 6869794Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.Type: GrantFiled: June 4, 2002Date of Patent: March 22, 2005Assignee: Crucell Holland, B.V.Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
-
Patent number: 6740511Abstract: The present invention relates to a modified fiber of an adenovirus, comprising at least one mutation at one or more residues within the region of said fiber stretching from pleated sheet A to pleated sheet B, and including loop AB.Type: GrantFiled: July 30, 2001Date of Patent: May 25, 2004Assignees: Transgene S.A., European Molecular Biology Laboratory (EMBL)Inventors: Mark Johan Van Raaij, Stephen Cusack, Valérie Legrand, Philippe Leissner, Majid Mehtali
-
Publication number: 20040038205Abstract: The present invention relates to a modified fiber of an adenovirus, comprising at least one mutation at one or more residues within the region of said fiber stretching from pleated sheet A to pleated sheet B, and including loop AB.Type: ApplicationFiled: September 26, 2003Publication date: February 26, 2004Applicant: TRANSGENE, S.A.Inventors: Mark Johan Van Raaij, Stephen Cusack, Valerie Legrand, Philippe Leissner, Majid Mehtali